HUE051746T2 - Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére - Google Patents

Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére

Info

Publication number
HUE051746T2
HUE051746T2 HUE14853910A HUE14853910A HUE051746T2 HU E051746 T2 HUE051746 T2 HU E051746T2 HU E14853910 A HUE14853910 A HU E14853910A HU E14853910 A HUE14853910 A HU E14853910A HU E051746 T2 HUE051746 T2 HU E051746T2
Authority
HU
Hungary
Prior art keywords
masp
methods
conditions associated
complement activation
treating conditions
Prior art date
Application number
HUE14853910A
Other languages
English (en)
Inventor
Gregory Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of HUE051746T2 publication Critical patent/HUE051746T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE14853910A 2013-10-17 2014-10-17 Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére HUE051746T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361892283P 2013-10-17 2013-10-17
US201462020845P 2014-07-03 2014-07-03

Publications (1)

Publication Number Publication Date
HUE051746T2 true HUE051746T2 (hu) 2021-03-29

Family

ID=52828769

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14853910A HUE051746T2 (hu) 2013-10-17 2014-10-17 Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére

Country Status (24)

Country Link
US (3) US20150166675A1 (hu)
EP (2) EP3057993B1 (hu)
JP (3) JP2016539919A (hu)
KR (2) KR20220053057A (hu)
CN (2) CN105683219B (hu)
AU (2) AU2014337047B2 (hu)
BR (1) BR112016008409B1 (hu)
CA (1) CA2926385A1 (hu)
CL (2) CL2016000908A1 (hu)
CY (1) CY1123776T1 (hu)
DK (1) DK3057993T3 (hu)
ES (1) ES2829913T3 (hu)
HR (1) HRP20201733T1 (hu)
HU (1) HUE051746T2 (hu)
IL (2) IL283373B1 (hu)
LT (1) LT3057993T (hu)
MX (2) MX2016005017A (hu)
NZ (2) NZ757986A (hu)
PL (1) PL3057993T3 (hu)
PT (1) PT3057993T (hu)
RS (1) RS61351B1 (hu)
RU (2) RU2718850C2 (hu)
SI (1) SI3057993T1 (hu)
WO (1) WO2015058143A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
NZ709997A (en) 2011-04-08 2016-03-31 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ES2829913T3 (es) 2013-10-17 2021-06-02 Omeros Corp Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2
GEP20247583B (en) * 2015-11-09 2024-01-10 Univ Leicester Methods for treating condi tions associated with masp-2 dependent complement activation
AU2017205453B2 (en) * 2016-01-05 2020-03-12 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
US10870708B2 (en) * 2016-03-31 2020-12-22 University Of Leicester Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
BR112020003632A2 (pt) * 2017-08-25 2020-10-27 Omeros Corporation método de tratamento de um indivíduo que sofre ou corre risco de desenvolver ahus
CN108171772B (zh) * 2017-12-28 2021-11-19 中国地质调查局西安地质调查中心 利用mapGIS、CJKCOOR_Ver和DELF3D提取河流边界的方法
EP3836965A4 (en) * 2018-06-22 2022-04-20 Omeros Corporation MASP-2 INHIBITION COMPOSITIONS AND METHODS FOR TREATING VARIOUS THROMBOTIC DISORDERS AND DISEASES
CA3119655A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
CN111134250A (zh) * 2019-12-03 2020-05-12 海南大学 一种草地贪夜蛾幼虫食用人工饲料的配方和制作方法
AU2020398241A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
CA3159159A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
EP4069238A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
IL293551A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN115300608B (zh) * 2021-05-06 2023-06-02 四川大学 一种利用甘露糖结合凝集素阻断新冠病毒感染的方法
TW202334242A (zh) * 2021-12-10 2023-09-01 美商歐米諾斯公司 結合ｍａｓｐ－２的絲氨酸蛋白酶結構域的治療性抗體及其用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
ATE399025T1 (de) 1999-07-21 2008-07-15 Omeros Corp Spüllösungen und verfahren zur schmerzhemmung, entzündungshemmung und hemmung des knorpelabbaus
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
HUE024996T2 (hu) * 2003-05-12 2016-01-28 Helion Biotech Aps MASP-2 elleni antitestek
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) * 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
SI2446900T1 (sl) 2004-06-10 2017-08-31 Omeros Corporation Metode za zdravljenje stanj, povezanih z masp-2 odvisno aktivacijo komplementa
NZ614351A (en) * 2008-11-10 2015-05-29 Alexion Pharma Inc Methods and compositions for treating complement-associated disorders
AU2010272483B2 (en) 2009-07-17 2016-07-21 Omeros Corporation MASP isoforms as inhibitors of complement activation
CA2971474C (en) 2009-10-16 2022-11-22 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US8999340B2 (en) 2010-03-01 2015-04-07 Alexion Pharmaceuticals, Inc. Methods for treating multiorgan, systemic degos' disease with a complement inhibitor
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
NZ709997A (en) * 2011-04-08 2016-03-31 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
ME03755B (me) * 2011-05-04 2021-04-20 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
JP2013030593A (ja) 2011-07-28 2013-02-07 J Devices:Kk 半導体装置、該半導体装置を垂直に積層した半導体モジュール構造及びその製造方法
RS61755B1 (sr) 2012-06-18 2021-05-31 Omeros Corp Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
JP6654137B2 (ja) 2013-09-16 2020-02-26 チルドレンズ ホスピタル メディカル センター Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
ES2829913T3 (es) 2013-10-17 2021-06-02 Omeros Corp Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2
GEP20247583B (en) 2015-11-09 2024-01-10 Univ Leicester Methods for treating condi tions associated with masp-2 dependent complement activation

Also Published As

Publication number Publication date
JP7397037B2 (ja) 2023-12-12
CN105683219A (zh) 2016-06-15
BR112016008409B1 (pt) 2021-06-15
JP2020037568A (ja) 2020-03-12
NZ719476A (en) 2022-07-29
AU2014337047A1 (en) 2016-05-19
US20150166675A1 (en) 2015-06-18
ES2829913T3 (es) 2021-06-02
CN111588855A (zh) 2020-08-28
HRP20201733T1 (hr) 2021-02-05
EP3057993B1 (en) 2020-08-12
EP3057993A1 (en) 2016-08-24
BR112016008409A2 (pt) 2017-10-03
DK3057993T3 (en) 2020-11-16
JP6953498B2 (ja) 2021-10-27
IL283373B1 (en) 2024-04-01
IL245115B (en) 2022-05-01
RU2016118769A (ru) 2017-11-22
JP2016539919A (ja) 2016-12-22
AU2020203748B2 (en) 2022-08-04
IL283373A (en) 2021-07-29
IL245115A0 (en) 2016-06-30
US11525011B2 (en) 2022-12-13
AU2020203748A1 (en) 2020-06-25
RU2016118769A3 (hu) 2018-11-21
JP2022000467A (ja) 2022-01-04
RU2020111211A (ru) 2021-11-08
SI3057993T1 (sl) 2021-03-31
KR20220053057A (ko) 2022-04-28
LT3057993T (lt) 2020-11-25
US20240124611A1 (en) 2024-04-18
AU2014337047B2 (en) 2020-03-12
NZ757986A (en) 2022-07-29
CA2926385A1 (en) 2015-04-23
RS61351B1 (sr) 2021-02-26
EP3057993A4 (en) 2017-09-13
WO2015058143A1 (en) 2015-04-23
US20200157244A1 (en) 2020-05-21
CY1123776T1 (el) 2022-03-24
CL2018001557A1 (es) 2018-07-20
PT3057993T (pt) 2020-11-19
MX2021008044A (es) 2021-10-13
CL2016000908A1 (es) 2016-12-02
KR20160062186A (ko) 2016-06-01
MX2016005017A (es) 2016-11-07
CN105683219B (zh) 2020-07-14
EP3750919A1 (en) 2020-12-16
RU2718850C2 (ru) 2020-04-15
PL3057993T3 (pl) 2021-02-08

Similar Documents

Publication Publication Date Title
LT3057993T (lt) Gydymo būdai būklių, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu
HK1250342A1 (zh) 用於治療與masp-2依賴性補體活化相關的狀況的方法
IL278018A (en) Methods for the treatment or prevention of ophthalmological conditions
GB2528196B (en) Multiple-qubit wave-activated controlled gate
SG10202011469UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
GB201312991D0 (en) Process
EP2945639A4 (en) METHOD FOR THE TREATMENT OF HEART DISEASES
HK1215164A1 (zh) 處理方法
GB201307334D0 (en) Process
GB201304872D0 (en) Treatment
GB201316269D0 (en) Process
GB201313915D0 (en) Process
HK1216391A1 (zh) 組合治療
EP2941270A4 (en) METHODS FOR TREATING INFLAMMATION
GB201314334D0 (en) Process
GB201300537D0 (en) Crosslinking process
GB201302441D0 (en) Process
GB201307327D0 (en) Process
GB201300073D0 (en) Process
PL2836176T3 (pl) Sposób leczenia starczowzroczności
GB201314561D0 (en) Process
GB201307310D0 (en) Treatment
GB201307951D0 (en) Process
GB201316253D0 (en) Process
GB201322764D0 (en) Treating places